Skip to Main Content

Author Details

Grant A McArthur
University of Melbourne
1986
312
81
PMIDPaper TitleJournal TitlePublished Year
38006317Validation of epidermal AMBRA1 and loricrin (AMBLor) as a prognostic biomarker for nonulcerated American Joint Committee on Cancer stage I/II cutaneous melanoma.Br J Dermatol2024
38006317Validation of epidermal AMBRA1 and loricrin (AMBLor) as a prognostic biomarker for nonulcerated American Joint Committee on Cancer stage I/II cutaneous melanoma.Br J Dermatol2024
36460017Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF<sup>V600</sup> mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.Lancet Oncol2023
35815337Prospective comparison of volumetric post-contrast T1-Sampling Perfection with Application optimized Contrasts by using different flip angle Evolutions and Magnetization-Prepared Rapid Acquisition with Gradient Echo in patients with metastatic melanoma.Neuroradiol J2023
37620155Prospective Comparison of T1-SPACE and MPRAGE for the Identification of Intrinsic T1 Hyperintensity in Patients with Intracranial Melanoma Metastases.AJNR Am J Neuroradiol2023
36967556The therapeutic potential of targeting minimal residual disease in melanoma.Clin Transl Med2023
36889810Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy.J Immunother Cancer2023
36638198A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study.Clin Cancer Res2023
37132182Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy.Immunotherapy2023
37116111Neoadjuvant Immunotherapy in Melanoma: The Paradigm Shift.Am Soc Clin Oncol Educ Book2023
36460017Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF<sup>V600</sup> mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.Lancet Oncol2023
36854080Combination Immune Checkpoint Inhibition: Is First Line Best?J Clin Oncol2023
37620155Prospective Comparison of T1-SPACE and MPRAGE for the Identification of Intrinsic T1 Hyperintensity in Patients with Intracranial Melanoma Metastases.AJNR Am J Neuroradiol2023
35815337Prospective comparison of volumetric post-contrast T1-Sampling Perfection with Application optimized Contrasts by using different flip angle Evolutions and Magnetization-Prepared Rapid Acquisition with Gradient Echo in patients with metastatic melanoma.Neuroradiol J2023
37116111Neoadjuvant Immunotherapy in Melanoma: The Paradigm Shift.Am Soc Clin Oncol Educ Book2023
37132182Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy.Immunotherapy2023
36967556The therapeutic potential of targeting minimal residual disease in melanoma.Clin Transl Med2023
36889810Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy.J Immunother Cancer2023
36854080Combination Immune Checkpoint Inhibition: Is First Line Best?J Clin Oncol2023
36638198A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study.Clin Cancer Res2023
34818112Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.J Clin Oncol2022
35699599First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.Clin Cancer Res2022
35444175Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?NPJ Precis Oncol2022
35383113Characterization of the treatment-naive immune microenvironment in melanoma with <i>BRAF</i> mutation.J Immunother Cancer2022
35618509Clinical validation and implementation of droplet digital PCR for the detection of BRAF mutations from cell-free DNA.Pathology2022
35366166Triplet Therapy in Melanoma - Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies.Curr Oncol Rep2022
35550554Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment.J Immunother Cancer2022
35793872Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma.J Immunother Cancer2022
35979667Correlation of MRI signal characteristics of intracranial melanoma metastases with BRAF mutation status.Melanoma Res2022
35232962Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAF<sup>V600</sup> melanoma.Nat Commun2022
34952480Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.Eur J Cancer2022
35131452Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAF<sup>V600</sup> mutation-positive melanoma.Ann Oncol2022
34937664BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting.Pathology2022
34818112Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.J Clin Oncol2022
35444175Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?NPJ Precis Oncol2022
35550554Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment.J Immunother Cancer2022
35383113Characterization of the treatment-naive immune microenvironment in melanoma with <i>BRAF</i> mutation.J Immunother Cancer2022
35793872Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma.J Immunother Cancer2022
35699599First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.Clin Cancer Res2022
35366166Triplet Therapy in Melanoma - Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies.Curr Oncol Rep2022
35618509Clinical validation and implementation of droplet digital PCR for the detection of BRAF mutations from cell-free DNA.Pathology2022
35979667Correlation of MRI signal characteristics of intracranial melanoma metastases with BRAF mutation status.Melanoma Res2022
35131452Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAF<sup>V600</sup> mutation-positive melanoma.Ann Oncol2022
34952480Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.Eur J Cancer2022
34937664BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting.Pathology2022
35232962Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAF<sup>V600</sup> melanoma.Nat Commun2022
33207293Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia.Eur J Cancer2021
33624884Decline in cancer pathology notifications during the 2020 COVID-19-related restrictions in Victoria.Med J Aust2021
33572972CDK4/6 Inhibition Reprograms Mitochondrial Metabolism in BRAF<sup>V600</sup> Melanoma via a p53 Dependent Pathway.Cancers (Basel)2021
341583605-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study.Clin Cancer Res2021
  • 1 - 50 of 624

Recommended Authors

Malaka Ameratunga
Australia Central Clinical School, Monash University
Career Start Year 2014
Number of shared co-authors 1
Brian J Capaldo
Center for Cancer Research, National Cancer Institute
Career Start Year 2012
Number of shared co-authors 0
Manoela Tiago
Thomas Jefferson University
Career Start Year 2011
Number of shared co-authors 7
Anusha Kalbasi
Stanford Cancer Institute, Stanford School of Medicine
Career Start Year 2010
Number of shared co-authors 5
Gareth Rivalland
Auckland City Hospital
Career Start Year 2010
Number of shared co-authors 4
Alan H Bryce
Mayo Clinic
Career Start Year 2006
Number of shared co-authors 3
Christine A Pratilas
Johns Hopkins University School of Medicine
Career Start Year 2004
Number of shared co-authors 7
Harriet M Kluger
Yale School of Medicine
Career Start Year 2003
Number of shared co-authors 14
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2002
Number of shared co-authors 12
Chi-Ping Day
Center for Cancer Research, National Cancer Institute
Career Start Year 2002
Number of shared co-authors 8
Daniel Zingg
Netherlands Cancer Institute
Career Start Year 2001
Number of shared co-authors 4
David J Liewehr
Center for Cancer Research
Career Start Year 1999
Number of shared co-authors 2
Travis J Hollmann
Memorial Sloan Kettering Cancer Center
Career Start Year 1998
Number of shared co-authors 15
Yardena Samuels
Weizmann Institute of Science
Career Start Year 1998
Number of shared co-authors 18
Cindy Sander
UPMC Hillman Cancer Center
Career Start Year 1997
Number of shared co-authors 7
Anthony M Joshua
The Kinghorn Cancer Centre, St. Vincent's Hospital Sydney
Career Start Year 1997
Number of shared co-authors 7
Katherine S Panageas
Memorial Sloan Kettering Cancer Center
Career Start Year 1996
Number of shared co-authors 16
Takami Sato
Sidney Kimmel Cancer Center, Thomas Jefferson University
Career Start Year 1995
Number of shared co-authors 9
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1994
Number of shared co-authors 2
Timothy A Chan
Cleveland Clinic.
Career Start Year 1994
Number of shared co-authors 26
Richard W Joseph
Mayo Clinic Hospital
Career Start Year 1994
Number of shared co-authors 7
Craig Gedye
Hunter Medical Research Institute, University of Newcastle
Career Start Year 1993
Number of shared co-authors 4
Suresh Nair
Lehigh Valley Topper Cancer Institute
Career Start Year 1990
Number of shared co-authors 7
Emile E Voest
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 4
Jose A Lopez-Martin
Hospital Universitario 12 de Octubre
Career Start Year 1988
Number of shared co-authors 0
Daniel S Peeper
Netherlands Cancer Institute
Career Start Year 1987
Number of shared co-authors 11
Craig L Slingluff
University of Virginia
Career Start Year 1987
Number of shared co-authors 11
Seth M Steinberg
Center for Cancer Research, National Cancer Institute
Career Start Year 1984
Number of shared co-authors 6
Dave S B Hoon
Saint John's Cancer Institute at Saint John's Health Center
Career Start Year 1982
Number of shared co-authors 21
Antonio Jimeno
University of Colorado School of Medicine
Career Start Year 1974
Number of shared co-authors 6

Collaborators

Antoni Ribas
University of California Los Angeles (university of california los angeles)
Co-authored papers 44
Georgina V Long
Co-authored papers 39
Karen E Sheppard
Co-authored papers 29
Richard B Pearson
Co-authored papers 24
Jonathan Cebon
Australia Olivia Newton-John Cancer Research Institute, La Trobe University
Co-authored papers 21
Caroline Robert
Co-authored papers 19
Dirk Schadendorf
Co-authored papers 19
Ricky W Johnstone
The University of Melbourne
Co-authored papers 18
Reinhard Dummer
University Hospital Zurich
Co-authored papers 17
Benjamin Solomon
Peter MacCallum Cancer Centre
Co-authored papers 17
Rory Wolfe
Co-authored papers 13
Anthony T Papenfuss
Co-authored papers 12
Damien Kee
Co-authored papers 12
Richard A Scolyer
Co-authored papers 11
Rene Gonzalez
University of Colorado Anschutz Medical Campus
Co-authored papers 11
Peter Hersey
Co-authored papers 10
Carl R Walkley
Co-authored papers 8
John M Kirkwood
UPMC Hillman Cancer Center
Co-authored papers 7
David D L Bowtell
Peter MacCallum Cancer Centre
Co-authored papers 6
Nicholas K Hayward
QIMR Berghofer Medical Research Institute
Co-authored papers 6
Anna C Pavlick
Co-authored papers 5
Stuart J Gallagher
Co-authored papers 5
George Au-Yeung
The University of Melbourne
Co-authored papers 4
Bartosz Chmielowski
Jonsson Comprehensive Cancer Center, University of California Los Angeles
Co-authored papers 4
Kaylene J Simpson
The University of Melbourne, Peter MacCallum Cancer Centre
Co-authored papers 3
David M Thomas
Garvan Institute of Medical Research
Co-authored papers 3
Meenhard Herlyn
Ellen and Ronald Caplan Cancer Center, The Wistar Institute
Co-authored papers 3
Christopher L Corless
Oregon Health & Science University
Co-authored papers 3
Luciano G Martelotto
Monash University
Co-authored papers 3
Katherine L Nathanson
Perelman School of Medicine, University of Pennsylvania, USA Abramson Cancer Center
Co-authored papers 3
Release 1.2